Rising Prevalence of Glioblastoma Multiforme Triggers Development of Novel Therapeutics

Published on : Jul 09, 2018

Albany, New York, July 9, 2018: Higher prevalence of glioblastoma multiforme, a rapidly spreading brain tumor, has been witnessed across the globe, especially in developed countries. For instance, according to WHO, about 10,000 cases of glioblastoma multiforme are diagnose on an annual basis in United States alone Moreover, the National Cancer Institute revealed that GBM or glioblastoma multiforme has an incidence rate of two to three individuals per 100,000 adults annually at global level and glioblastoma multiforme accounts for around 17 percent of the brain tumors, including both metastatic and primary brain cancers. That said, pharmaceutical companies are striving to develop advanced therapeutics to facilitate effective treatment of this type of cancer. A new research report showcasing pipeline review for H1 2018 for glioblastoma multiforme titled “Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2018” has been added to the research repository of Market Research Hub (MRH).

Typically occurring between ages of 45 and 70, likelihood of development of glioblastoma multiforme in aged people is higher as compared to adults. This has caused a sense of concern among nations with higher aged population, such as Japan, which led to the development of novel therapeutics to treat the disease.

With an increased focus on research and development, various companies are trying different possibilities for treatment in the gene therapy and molecular biotechnology space in order to find innovative possibilities for GBM treatment. The glioblastoma multiforme pipeline review for H1 2018 includes analysis associated with development of therapeutics, their assessment along with various drugs used in treatment of glioblastoma multiforme.

Glioblastoma Multiforme Pipeline Review- H1, 2018: Report Overview

The report on glioblastoma multiforme pipeline review for H1, 2018 begins with a brief introduction on the overall glioblastoma multiforme scenario. The introduction section of the report covers a general overview of the market, followed by intelligence on therapeutics development, therapeutics assessment, various companies involved in the development of therapeutics for glioblastoma multiforme, drug profiles used in glioblastoma multiforme treatment, dormant and discontinued projects and product development milestones.

The research report on glioblastoma multiforme pipeline review, H1 2018, offers a complete intelligence assessment on therapeutics under development along with stages of development, target drug, MoA (Mechanism of Action), RoA (Route of Administration) and molecule type. The report also covers vivid pharmacological action of therapeutics, complete research of this pharmacological action and history of development along with latest press releases and news.

Glioblastoma Multiforme Pipeline Review- H1, 2018: Companies Involved in Development

The report on glioblastoma multiforme pipeline review, H1, 2018, includes analysis on various companies involved in development of glioblastoma multiforme therapeutics. The section reveals therapeutics under development by universities, companies and institutes, development of molecules by companies in phase 3, phase 2, phase 1, phase 0, CTA/IND Filed, discovery, preclinical and unknown stages. Likewise, all these aspects are taken into consideration with respect to university trials for glioblastoma multiforme pipeline development.

The report on glioblastoma multiforme pipeline review, H1 2018, supports the reader in tracking and identifying evolving players in the glioblastoma multiforme market that facilitates in effective decision making in order to create efficient counter strategies to gain competitive edge. This report is fabricated using registries of clinical trials, SEC filings, conferences, university and company websites, investor presentations and press releases.

Glioblastoma Multiforme Pipeline Review- H1, 2018: Reasons to Invest in This Study

This report covers in-depth intelligence on various clinical trials revealing pipeline analysis for glioblastoma multiforme during H1 of 2018. In addition, the report on glioblastoma multiforme pipeline analysis, H1 2018, includes analysis on dormant projects or discontinued projects that can be used by upcoming companies as a new opportunity in this space.  

Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1843573

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top